ENVB Company Profile and Key Details

ENVB has shown mixed momentum, gaining 5.76% over the past week and -55.65% over the past quarter, though year-to-date performance is up 11.29%. Short-term trend indicators are bullishly aligned (SMA20 -3.55%, SMA50 -34.37%, SMA200 -75.49%). The stock’s 14-day RSI is 39.65 (weak momentum), while the ATR of 0.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.7% below its high and over 18.37% above its low. Average 10-day trading volume of 2.43 million shares is significantly above the 3-month average of 576.86 thousand, indicating heightened recent market interest.

Enveric Biosciences, Inc. has 2.47 million shares outstanding. The public float is 3.22 million shares, elevated short interest at 10.42% of float. This equals 255.06 thousand shares. The short ratio is 1.54 days. Institutional investors hold 10.95% of the float. Insiders own 6.84%. Sikaria Chanda holds 2.25 million shares, Sikaria Family 2008 Revocable Trust Dated 02/28/2008 has 2.25 million shares and Lokesh Sikaria Trust Dated 12/14/2012 has 2.25 million shares.

Enveric Biosciences, Inc. generated EPS of -$94.85 over the past year. Five-year average earnings growth is 57.47%. The latest quarter delivered EPS of -$10.81. The next quarter is forecast at $nan. Next year's EPS is expected at $59.18. Enveric Biosciences, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 14, 2025, missed forecasts by -82.84%. The prior quarter beat by -81.52%. Over the last six quarters, Apple has recorded several small beats. These include -54.55% in August 12, 2024.

Enveric Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.06. This means the shares are trading above this model’s fair value.

Enveric Biosciences, Inc. (NASDAQ:ENVB) closed at $4.19 USD, gaining $2.37 (130.30%) from the previous close of $1.82. The stock is currently mid-range between its 52-week high and low $1.71 and $17.84. With a market capitalization of about $2.50 million, Enveric Biosciences, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 561.87 thousand shares, trading with heavier-than-usual volume. Headquartered in Naples, FL, Enveric Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joseph Edward Tucker, the company employs approximately 5 people and listed since May 04, 2015. Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care.

Enveric Biosciences, Inc. trades at a P/E ratio of -0.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.46 suggesting the stock is closer to book value. The P/FCF stands at -0.13, also above market averages.

Our AI price prediction model suggests that Enveric Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.34%, with price expected at $1.99 by May 01, 2026, within a range of $1.87 to $2.12 3-Month Outlook: Projected fall of -21.43%, reaching $1.43 by July 16, 2026, with a range of $0.22 to $2.47. 1-Year Outlook: Projected loss of -96.7%, with price at $0.06 by April 16, 2027, within a range of $0.00 to $10.00.

Enveric Biosciences, Inc. (NASDAQ:ENVB) shares are up 11.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Enveric Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.00, suggesting 449.45% upside. Our AI forecast model points to short-term strength (9.34% over two weeks), a medium-term fall (-21.43% over three months), and a longer-term loss (-96.7% over one year), with expected trading ranges indicating moderate volatility.